NASDAQ:MDRX Veradigm (MDRX) Stock Price, News & Analysis $4.95 +0.05 (+1.02%) As of 10/23/2026 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsNews and TrendsSEC Filings About Veradigm Stock (NASDAQ:MDRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Veradigm alerts:Sign Up Key Stats Today's Range$4.75▼$4.9550-Day Range$4.55▼$5.1452-Week Range$3.25▼$6.00Volume47,841 shsAverage Volume119,157 shsMarket Capitalization$605.39 millionP/E Ratio23.25Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Veradigm Inc. (NASDAQ:MDRX), formerly known as Allscripts Healthcare Solutions, is a healthcare technology company that provides software, data and connectivity solutions for healthcare organizations, physicians, patients, payers and life sciences companies. The company changed its name to Veradigm in 2023 to reflect its broader focus on using healthcare data to support clinical, operational and commercial decision-making. Veradigm’s offerings include electronic health record and practice-management solutions, electronic prescribing, revenue-cycle and financial management tools, patient engagement services and healthcare information-exchange capabilities. Its portfolio has included products and platforms such as Veradigm EHR, Practice Fusion and FollowMyHealth, which are designed to support clinical workflows, patient communication and access to health information. The company also develops data and analytics solutions for payers and life sciences organizations, including tools intended to help analyze real-world healthcare information, improve care coordination and support population-health initiatives. Veradigm primarily serves the U.S. healthcare market through relationships with medical practices, hospitals, health plans, pharmaceutical companies and other healthcare stakeholders.AI Generated. May Contain Errors. Read More Receive MDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veradigm and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDRX Stock News HeadlinesVeradigm Product Portfolio Achieves HITRUST i1 CertificationOctober 21 at 5:57 PM | finance.yahoo.comVeradigm reports limited patient data cybersecurity breachSeptember 10, 2026 | theglobeandmail.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.October 24 at 1:00 AM | Profits Run (Ad)Veradigm Announces Updated Presentation Time for Upcoming Investor ConferenceSeptember 8, 2026 | finance.yahoo.comVeradigm to Participate in Two Upcoming Investor ConferencesAugust 17, 2026 | businesswire.comVeradigm Extends Stockholder Board Observer Agreement Through 2026June 26, 2026 | tipranks.comVeradigm Inc. (MDRX) Discusses Progress on SEC Filings, Relisting Efforts and Strategic Update TranscriptMay 28, 2026 | seekingalpha.comVeradigm Files 2023 and 2024 Form 10-KMay 26, 2026 | businesswire.comSee More Headlines MDRX Stock Analysis - Frequently Asked Questions How have MDRX shares performed this year? Veradigm's stock was trading at $4.60 at the beginning of 2026. Since then, MDRX shares have increased by 7.6% and is now trading at $4.95. How were Veradigm's earnings last quarter? Veradigm Inc. (NASDAQ:MDRX) issued its quarterly earnings results on Thursday, November, 4th. The software maker reported $0.27 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.09. The company's revenue was down 8.2% on a year-over-year basis. Does Veradigm have any subsidiaries? The following companies are subsidiaries of Veradigm: ZappRx, HealthGrid, and Practice Fusion. How do I buy shares of Veradigm? Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Veradigm own? Based on aggregate information from My MarketBeat watchlists, some other companies that Veradigm investors own include AT&T (T), Netflix (NFLX), Hewlett Packard Enterprise (HPE), Advanced Micro Devices (AMD), Costco Wholesale (COST), FuelCell Energy (FCEL) and Gilead Sciences (GILD). Company Calendar Last Earnings11/04/2021Today10/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Technology Sub-IndustryHealthcare Technology Current SymbolNASDAQ:MDRX CIK1124804 Webveradigm.com Phone(800) 334-8534Fax313-322-9600Employees2,300Year Founded1986Profitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio23.25 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.53 billion Price / Sales0.40 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares122,300,000Free Float105,175,000Market Cap$605.39 million OptionableNo Data Beta0.51 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:MDRX) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veradigm Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veradigm With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
